(
91
Results
)
Filter
Only match titles
What are you looking for?
-
Category
-
Type
-
Year
-
Keywords
Apply filters
Website
Collapse
-
“All-You-Can-Eat”: Omalizumab as a Curative Treatment for Severe Food Allergies – A Case Report
-
“Evaluating Inflammatory Markers in Chronic Spontaneous Urticaria: Impact of Omalizumab Treatment”
-
A retrospective analysis of patients with chronic spontaneous urticaria in treatment with Omalizumab conducted in Brescia
-
Acute Episode of Anaphylaxis Successfully Controlled with Omalizumab
-
Analysis of discontinuation of omalizumab in patients with chronic spontaneous and/or inducible urticaria in a tertiary hospital in one year
-
Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria
-
Beneficial role of Psychotherapeutic Interventions in Managing Chronic Spontaneous Urticaria Refractory to Omalizumab – A Case Study
-
Benralizumab in Omalizumab refractory chronic spontaneous urticaria – A Case Series of 4 Patients in Portugal
-
Beyond the Rash: How Omalizumab Shapes Mental Health Outcomes in Chronic Spontaneous Urticaria
-
Budget impact of omalizumab biosimilar from the French healthcare perspective
-
Can factors associated with relapse be predicted in patients with increased omalizumab dose intervals?
-
Changes in Treatment Landscape of Urticaria : Clinical Data of Omalizumab Biosimilar
-
Characterization of the clinical phenotype of patients with CSU treated with cyclosporin alone or combined with omalizumab
-
Chronic Urticaria Activity in Patients Treated with Omalizumab at Bellvitge University Hospital (HUB)
-
Comparable Efficacy and Pharmacodynamic Results of CT-P39 to Reference Omalizumab in Patients with Chronic Spontaneous Urticaria
-
Comparative Efficacy and Safety of Omalizumab Intended copy Biosimilar vs. Biologic in Chronic Spontaneous Urticaria
-
Comparison of the efficacy of omalizumab and mepolizumab in non-steroidal anti-inflammatory drug-exacerbated respiratory disease
-
Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria
-
Delayed-Type Hypersensitivity to Omalizumab
-
Delayed-Type Hypersensitivity to Omalizumab
-
Effect of Omalizumab on Inflammatory and Immune Biomarkers in Mast Cell-Mediated Angioedema
-
Effects of Omalizumab on Human Basophils in Children with Cow’s Milk Protein Allergy
-
Efficacy and Safety Analysis of Omalizumab in Treating Wheat-Dependent Exercise-Induced Anaphylaxis (WDEIA) in the Chinese Population
-
Efficacy and Safety of Omalizumab in Treating Severe Allergic Reactions with Urticaria as the Initial Symptom
-
Efficacy and safety of Omalizumab in a Patient, previously undergoing liver transplantation, with facial angioedema, unresponsive to corticosteroids and antihistamines
-
Efficacy and safety of dupilumab versus omalizumab in patients with severe chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): Results from a prospective, head-to-head phase 4 trial
-
Efficacy and safety of therapy with omalizumab in children with chronic spontaneous urticaria
-
Efficacy of Omalizumab in Food Allergy Management in a Patient with Chronic Spontaneous Urticaria
-
Efficacy of Omalizumab in Refractory Chronic Rhinosinusitis with Nasal Polyps and Association with Local Immunoglobulin E
-
Evaluation of the Effectiveness of Omalizumab in Treating Cypress Pollen Allergic Rhinoconjunctivitis with Total IgE Levels Below 30IU/ml
-
Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab
-
Exploring potential predictive factors for time to response to Omalizumab treatment in a Romanian subset of patients with Chronic Spontaneous Urticaria
-
FERMAH-OIT: Food Extensive Rapid Multi-Allergen Home Oral Immunotherapy; A novel OIT protocol without OmalizumabFERMAH-OIT: Food Extensive Rapid Multi-Allergen Home Oral Immunotherapy; A novel OIT protocol without Omalizumab
-
Future Treatment Landscape with Omalizumab Biosimilar in Asthma
-
Hereditary α-Tryptasemia in Severe Allergic Asthma: Impaired Lung Function, Reduced Type 2 Biomarkers, and Suboptimal Omalizumab Response
-
High-affinity omalizumab variants with optimized disruptive efficacy accelerate allergic effector cell desensitization
-
IgE and Eosinophils levels may predict Successful Omalizumab withdrawal in chronic spontaneous urticaria
-
Impact of Omalizumab on Serum IgE Levels: An Observational Cohort Study
-
Impact of Switching from Omalizumab to Dupilumab in Severe Asthma Patients: A Retrospective Evaluation of Efficacy and Inflammatory Biomarkers
-
Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab
-
Multi-omic analyses reveal new potential biomarkers for monitoring asthmatic patients treated with either Mepolizumab or Omalizumab
-
Multi-omic analyses reveal new potential biomarkers for monitoring asthmatic patients treated with either Mepolizumab or Omalizumab
-
Omalizumab Combined Chinese Traditional Medicine in a Complicated Severe Asthma after Bronchial Thermoplasty
-
Omalizumab Efficacy in Relapse of Nasal Polyposis
-
Omalizumab Reduces Anaphylactic Reactions and Facilitates Food Introduction in Food-Allergic Children with Severe Asthma: A Case Report
-
Omalizumab Treatment in Pediatric Patients with Chronic Urticaria: 6 years Real life Data
-
Omalizumab Use in Pediatric Chronic Urticaria, A Retrospective Study from a Tertiary Hospital
-
Omalizumab Use in Pediatric Chronic Urticaria, A Retrospective Study from a Tertiary Hospital
-
Omalizumab administration for the management of severe allergic keratoconjunctivitis – a 10-year experience
-
Omalizumab and chronic spontaneous urticaria: ‘one dose does not fit all’
-
Omalizumab as a diagnostic and therapeutic trial for recurrent idiopathic angioedema
-
Omalizumab as a diagnostic and therapeutic trial for recurrent isolated angioedema: a retrospective observational study
-
Omalizumab as an off-label prescription for pediatric patients
-
Omalizumab for oral desensitization in children with cow’s milk allergy
-
Omalizumab in CSU: analysis of potential markers of response
-
Omalizumab in Food allergy – a retrospective analysis
-
Omalizumab in Food allergy – a retrospective analysis
-
Omalizumab in children with allergic severe asthma, food allergies and IgE Levels >1,500 kU/L: a two-year-long evaluation
-
Omalizumab in food allergy
-
Omalizumab to the rescue for severe anaphylaxis in desensitization to carboplatin
-
Optimizing Omalizumab Therapy in Chronic Urticaria: Tailored Approaches for Weaning and Sustained Remission
-
Oral Immunotherapy with omalizumab in an adult patient with severe milk and egg allergy
-
Predicting Responses to Omalizumab in Antihistamine-Refractory Chronic Urticaria
-
Predictors of Relapse After Omalizumab Withdrawal in Adults with CSU with complete response to treatment
-
Progressive increase of the intervals between omalizumab administration in severe asthma
-
Protocol for a randomized, 5-arm study to evaluate the combination of omalizumab and allergen immunotherapy in patients with asthma due to house dust mites
-
Rapid drug desensitization with chemotherapy: When should omalizumab be considered?
-
Real-Life Effectiveness of Mepolizumab and Omalizumab in Sever Uncontrolled Chronic Rhinosinusitis with Nasal Polyps: A Prospective Study
-
Real-World Evaluation of Omalizumab in Chronic Spontaneous and Inducible Urticaria: A Longitudinal Analysis during 15 years from a Lisbon UCARE
-
Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria
-
Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria
-
Response to benralizumab in severe vernal keratoconjunctivitis after treatment failure with omalizumab
-
Safety and effectiveness of Omalizumab for Cold Urticaria in pediatric age
-
Severe Milk Allergy: Outcame of OIT with Omalizumab in a Real Life setting. Seven years follow up
-
Severe asthma in pediatrics and Dupilumab after failure with Omalizumab
-
Should Omalizumab Therapy Be Discontinued?
-
Specific IgE and IgG4 changes in adults undergoing peanut immunotherapy combined with omalizumab
-
Stop omalizumab in a pediatric population with severe asthma: A retrospective monocenter study
-
Succesful Omalizumab Desensitization in Two Children with Severe Allergic Asthma and Cronic Spontaneous Urticaria
-
Successful administration of omalizumab following anaphylaxis in a patient with chronic idiophatic urticaria
-
Successful immunotherapy with cow’s milk and omalizumab in a 24-year-old patient with extreme cow’s milk allergy
-
Taking a closer look to the first EMA-approved omalizumab biosimilar in Chronic Spontaneous Urticaria
-
The Role Of Omalizumab In Idiopathic Mast Cell Activation Syndrome
-
The association between baseline IgE levels and response to standard-dose omalizumab in uncontrolled chronic urticaria patients
-
The association between baseline IgE levels and response to standard-dose omalizumab in uncontrolled chronic urticaria patients
-
Transforming Healthcare: The Introduction of the First Omalizumab Biosimilar
-
Treatment of Chronic Spontaneous Urticaria with Omalizumab Complicated by Onychodystrophy?
-
Treatment of Chronic Spontaneous Urticaria with Omalizumab during Pregnancy- Experience in a Portuguese Ucare
-
Treatment with Omalizumab in chronic spontaneous urticaria: experience in a tertiary hospital
-
Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic
Show more Sessions (88)Show Less-
